Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Metabolic Disorders

Set Alert for Metabolic Disorders

Novo Touts Diabetes R&D As Ozempic Faces Lilly Challenger

The Danish major highlighted a spate of diabetes pipeline updates during its second quarter earnings as blockbuster drug Ozempic grappled with a new rival in the shape of Lilly’s Mounjaro.

Companies Metabolic Disorders

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast version of Five Must-Know Things: planned US drug pricing legislation in focus; solid quarter but no Seagen announcement for Merck & Co; AbbVie’s Gonzalez sounds alarm over US pricing legislation; Alnylam ready to expand in amyloidosis; and Boehringer Ingelheim on global Jardiance strategy.

Pricing Debate Sales & Earnings

AdipoPharma Targets Root Cause Of Diabetes With First ‘Adipeutic’ Drug Candidate

Emerging Company Profile: The French biotech is developing a constrained peptide that targets an interaction in body fat tissue in the hopes of treating type 2 diabetes.

Emerging Company Profile Metabolic Disorders

As Lilly’s Realized Sales Prices Drop, Ricks Reiterates Criticism Of US Drug Price Plan

With Lilly’s sales narrative hampered by global price pressures, Lilly CEO David Ricks again criticized drug price negotiation proposals before Congress. Mounjaro launch offers a bright spot, exceeding projections.

Sales & Earnings Business Strategies

Wegovy Manufacturing Issues Continue To Hamper Novo Nordisk

Danish pharma says it will not market the weight-loss formulation of semaglutide until manufacturing can meet demand. Novo has seen significant growth in GLP-1 franchise in both diabetes and obesity.

Sales & Earnings Business Strategies

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast version of Five Must-Know Things: Novo obesity drugs in US cost-effectiveness spotlight; Biogen’s growth challenges; Novartis’s view on large M&A; pharma’s Q2 outlook; and MSD on Lagevrio.

M & A Business Strategies

Novo Nordisk's Obesity Drugs Exceed ICER’s Cost Effectiveness Thresholds

Wegovy and Saxenda surpass cost effectiveness thresholds at current prices, while two widely unused drugs, Qysmia and Contrave, are cost-effective at accepted benchmarks, according to a draft report from the Institute for Clinical and Economic Review.

Cost Effectiveness Metabolic Disorders

Rhythm Eyes Bigger Market For Imcivree Following Phase II Hypothalamic Obesity Promise

The US firm’s Imcivree has impressed with interim mid-stage data from a hypothalamic obesity study, paving the way for pivotal success that could open up a much larger market.

Clinical Trials Metabolic Disorders

Vertex Builds Type 1 Diabetes Reach And Flexibility With ViaCyte

Vertex will pay $320m to buy rival ViaCyte, which is developing stem cell therapies for type 1 diabetes, to complement internal work on VX-880, the firm announced.

Deals M & A

Vertex Diabetes Cell Therapy Back On Track After FDA ‘Hiccup’

The US firm has received the FDA thumbs-up to continue a trial for its novel cell therapy candidate, VX-880, after what was perceived in some circles as an over-cautious decision by the regulator to pause the study in March.

Clinical Trials Metabolic Disorders

Rhythm Leans On Imcivree Rare Disease Commercialization For New Indication

The company got FDA approval for the drug in Bardet-Biedl syndrome, on top of the existing approval from November 2020 in obesity due to POMC, PCSK1 and LEPR deficiency.

Rare Diseases Approvals

Novo’s Sogroya Impresses In Children With Convenience Advantage Over SOC

The Danish firm’s injectable growth hormone analogue has succeeded in a late-stage study of children with a growth disorder and offers more convenient dosing that could improve adherence.

Clinical Trials Rare Diseases
See All
UsernamePublicRestriction

Register